Skip to main content
curacle co., ltd. logo

curacle co., ltd. — Investor Relations & Filings

Ticker · 365270 ISIN · KR7365270008 KO Professional, scientific and technical activities
Open in API
Filings indexed 203 across all filing types
Latest filing 2024-06-24 Regulatory Filings
Country KR South Korea
Listing KO 365270

About curacle co., ltd.

http://www.curacle.com/eng/main/

Curacle Co., Ltd. is a clinical-stage biopharmaceutical company focused on the research and development of innovative drugs for intractable vascular diseases. The company's core platform technology centers on developing highly effective protectors against endothelial dysfunction, a key factor in various age-related and vascular conditions. Its development pipeline includes novel treatments targeting significant unmet medical needs, with a particular focus on conditions such as Diabetic Macular Edema (DME), Wet Age-related Macular Degeneration (wet AMD), diabetes, and stroke. Curacle aims to create differentiated therapies through innovative targets and treatment concepts, including the development of orally administered medications for complex eye diseases.

Recent filings

Filing Released Lang Actions
[기재정정]불성실공시법인지정예고 (공시불이행)
Regulatory Filings Classification · 100% confidence The document is a regulatory notice from the Korea Exchange regarding a 'Notice of Designation as an Unfaithful Disclosure Corporation' (불성실공시법인지정예고). It details a correction to a previous filing and outlines the regulatory implications of non-compliance with disclosure rules. Since this is a specific regulatory announcement regarding compliance and disclosure status, it falls under the 'Regulatory Filings' category.
2024-06-24 Korean
불성실공시법인지정예고 (공시불이행)
Regulatory Filings Classification · 100% confidence The document is a formal notice from the Korea Exchange regarding the designation of Curacle as a 'non-compliant disclosure corporation' due to a delay in reporting a license-out agreement. This is a regulatory announcement concerning compliance and potential penalties, which fits the definition of a regulatory filing or notice that does not fall into specific financial reporting categories like 10-K or IR. Given the nature of the regulatory notification, 'RNS' (Regulatory Filings) is the most appropriate classification.
2024-06-20 Korean
[기재정정]투자판단관련주요경영사항 (당뇨병성 황반부종 및 습성 황반변성 치료제 CU06-RE 기술이전License-Out, L/O 계약해지 및 권리 반환)
M&A Activity Classification · 95% confidence The document is a regulatory filing from the Korean stock exchange (KRX) regarding a material management decision (License-Out contract termination). It details the cancellation of a technology transfer agreement for a drug candidate. Since it is a specific regulatory announcement regarding a material business event that does not fit into categories like M&A, dividends, or financial reports, it is classified as a general regulatory filing.
2024-06-14 Korean
[기재정정]투자판단관련주요경영사항 (당뇨병성 황반부종 및 습성 황반변성 치료제 CU06-RE 기술이전License-Out, L/O 계약해지 및 권리반환)
M&A Activity Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) regarding a material management decision (License-Out contract termination). It details the cancellation of a technology transfer agreement for a drug candidate. Since it is a specific regulatory announcement regarding a material business event that does not fit into categories like M&A, dividends, or financial reports, it is classified as a general regulatory filing.
2024-06-12 Korean
[기재정정]투자판단관련주요경영사항 (당뇨병성 황반부종 및 습성 황반변성 치료제 CU06-RE 기술이전License-Out, L/O 계약해지 및 권리반환)
M&A Activity Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) regarding a material management decision (License-Out contract termination). It details the termination of a licensing agreement for a drug candidate (CU06-RE). Since it is a specific regulatory announcement regarding a material business event that does not fit into categories like M&A, dividends, or financial reports, it is classified as a general regulatory filing.
2024-06-10 Korean
[기재정정]주식매수선택권행사
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from the Korean company Curacle regarding the exercise of stock options (주식매수선택권행사). It specifically details a correction (정정신고) to a previously filed report, updating the expected listing date for new shares issued through stock option exercises. Since this relates to the issuance of new shares resulting from stock options, it falls under the category of share issues and capital changes.
2024-06-04 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.